Development of a Multiplex Selected Reaction Monitoring Assay for Quantification of Biochemical Markers of Down Syndrome in Amniotic Fluid Samples

Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Journal of Proteome Research (Impact Factor: 4.25). 06/2012; 11(7):3880-7. DOI: 10.1021/pr300355a
Source: PubMed


Down syndrome (DS) is one of the most common chromosomal abnormalities affecting about 1 of every 700 fetuses. Current screening strategies have detection rates of 90-95% at a 5% false positive rate. The aim of this study was to discover new biomarkers of DS in amniotic fluid by using a multiplex selected reaction monitoring assay. Nine proteins were analyzed: CEL, CPA1, MUC13, CLCA1, MUC5AC, PLUNC, and HAPLN1, and CGB as positive control and serotransferrin as negative control. One proteotypic peptide for each protein was selected, and internal heavy isotope-labeled peptide standards were spiked into the samples. Fifty-four samples from pregnant women carrying normal (n = 37) or DS-affected (n = 17) fetuses were analyzed. The median protein concentrations for DS and normal samples, respectively, were as follows: 20 and 49 ng/mL (p < 0.01) for CEL; 3.7 and 14 ng/mL (p < 0.001) for CPA1; 80 and 263 ng/mL (p < 0.001) for MUC13; 46 and 135 ng/mL (p < 0.001) for CLCA1; 0.65 and 0.93 μg/mL (p < 0.05) for MUC5AC; 61 and 73 ng/mL (p > 0.05) for PLUNC; 144 and 86 ng/mL (p < 0.01) for HAPLN1; 0.89 and 0.54 μg/mL (p = 0.05) for CGB; 91 and 87 μg/mL (p > 0.05) for serotransferrin. Statistically significant differences were found in six out of the seven candidate proteins analyzed, reflecting a different regulation in DS.

Download full-text


Available from: Eduardo Martínez-Morillo, Dec 15, 2014
34 Reads
  • Source
    • "Likewise, extensive analysis of the amniotic fluid proteome was completed in order to identify biomarkers for diagnosis of Down syndrome and fetal diseases [58]. More than a thousand proteins were identified in the amniotic fluid of pregnant women carrying chromosomally normal fetuses and fetuses with Down syndrome at different gestational ages, and the most promising candidates were verified [52] [59] [60]. Since each type of biological sample has its own advantages and disadvantages , combination of complementary samples increases the likelihood to discover true positive markers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein biomarker development is a multidisciplinary task involving basic, translational and clinical research. Integration of multidisciplinary efforts in a single pipeline is challenging, but crucial to facilitate rational discovery of protein biomarkers and alleviate existing disappointments in the field. In this review, we discuss in detail individual phases of biomarker development pipeline, such as biomarker candidate identification, verification and validation. We focus on mass spectrometry as a principal technique for protein identification and quantification, and discuss complementary -omics approaches for selection of biomarker candidates. Proteomic samples, protein-based clinical laboratory tests and limitations of biomarker development are reviewed in detail, and critical assessment of all phases of biomarker development pipeline is provided. This article is part of a Special Issue entitled: Medical Proteomics.
    Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 09/2014; DOI:10.1016/j.bbapap.2014.09.006 · 2.75 Impact Factor
  • Source
    • "SRM methods were developed for verification of protein ratios in SF, following our in-house protocols [52]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Synovial fluid (SF) is a dynamic reservoir for proteins originating from the synovial membrane, cartilage, and plasma, and may therefore reflect the pathophysiological conditions that give rise to arthritis. Our goal was to identify and quantify protein mediators of psoriatic arthritis (PsA) in SF. Methods Age and gender-matched pooled SF samples from 10 PsA and 10 controls [early osteoarthritis (OA)], were subjected to label-free quantitative proteomics using liquid chromatography coupled to mass spectrometry (LC-MS/MS), to identify differentially expressed proteins based on the ratios of the extracted ion current of each protein between the two groups. Pathway analysis and public database searches were conducted to ensure these proteins held relevance to PsA. Multiplexed selected reaction monitoring (SRM) assays were then utilized to confirm the elevated proteins in the discovery samples and in an independent set of samples from patients with PsA and controls. Results We determined that 137 proteins were differentially expressed between PsA and control SF, and 44 were upregulated. The pathways associated with these proteins were acute-phase response signalling, granulocyte adhesion and diapedesis, and production of nitric oxide and reactive oxygen species in macrophages. The expression of 12 proteins was subsequently quantified using SRM assays. Conclusions Our in-depth proteomic analysis of the PSA SF proteome identified 12 proteins which were significantly elevated in PsA SF compared to early OA SF. These proteins may be linked to the pathogenesis of PsA, as well serve as putative biomarkers and/or therapeutic targets for this disease.
    Clinical Proteomics 07/2014; 11(1):27. DOI:10.1186/1559-0275-11-27
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study of interactions between genes and their environment, thus of molecules that form the "functional genome", has been greatly enhanced throughout the course of post-genomic era by the expansion of the -omic technologies. Proteomic technologies and mass spectrometry in particular, form a well-armoured strategy towards high-thoughput simultaneous analysis of thousands of proteins and protein-related molecules. Proteomics have in the past, and are currently offering novel perspectives in the understanding over the pathophysiology of malicious conditions as well as in the development of molecular targeted-therapeutics against them. This review examines the offerings of proteomics research over the unique physiological phenomenon of pregnancy and its related complications, which affect both maternal and perinatal health.
    Clinical biochemistry 10/2012; 46(6). DOI:10.1016/j.clinbiochem.2012.10.011 · 2.28 Impact Factor
Show more